<DOC>
	<DOCNO>NCT02436096</DOCNO>
	<brief_summary>The use low-dose CBP dose nightly bedtime FM support result Tonix ' TNX-CY-F202 Phase 2b study ( also refer BESTFIT Study ) . The TNX-CY-F202 study provide strong evidence TNX-102 SL 2.8 mg dose nightly result beneficial effect upon pain , sleep FM symptomatology . The present trial design assess safety efficacy TNX-102 SL 2.8 mg tablet , take daily bedtime 12 week treat fibromyalgia .</brief_summary>
	<brief_title>A Study Evaluate eFFIcacy Safety Sublingual TNX-102 SL Tablet Taken Bedtime Patients With fibRoMyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Neuromuscular Diseases</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Musculoskeletal Diseases</mesh_term>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Cyclobenzaprine</mesh_term>
	<criteria>Diagnosis Primary Fibromyalgia ( 2010 ACR criterion ) Male female 1875 year old For patient major depressive disorder : clinically stable , suicidal risk stable antidepressant therapy Willing able withdraw specific therapy ( ask PI ) Medically acceptable form contraception ( female ) Signed informed consent Arthritis , lupus systemic autoimmune diseases Regional persistent pain could interfere assessment fibromyalgia pain Bipolar psychotic disorder Increased risk suicide Significant clinical ( cardiac , systemic infection , systemic corticosteroid requirement , drug/alcohol abuse ) laboratory abnormality . Unability washout specific medication ( ask PI ) Known hypersensitivity cyclobenzaprine Others : seizure disorder , severe/untreated sleep apnea , BMI &gt; 40</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pain</keyword>
	<keyword>Sleep</keyword>
</DOC>